
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. is poised for growth, with Baqsimi sales projected to increase approximately 20% quarter-over-quarter in Q3 2025, bolstered by collaborations and seasonal demand. The company is expected to achieve flat year-over-year top-line results in 2025 followed by a return to double-digit growth in 2026, indicating a strong recovery trajectory. Furthermore, expectations of high-single digit unit growth for 2025, combined with the favorable seasonal performance of products like Primatene Mist, contribute to a positive outlook for Amphastar's financial future.
Bears say
Amphastar Pharmaceuticals Inc. is experiencing significant revenue pressures, particularly with iron sucrose and glucagon products, as increased competition and supply issues lead to a downward revision of expected sales from previously optimistic projections. The shift in market dynamics has resulted in a forecast that annual glucagon sales may drop below $70 million starting in 2026, indicating an unfavorable outlook driven by the entry of new competitors. Furthermore, expectations for a return to double-digit top-line growth have been tempered to a forecast of high-single digit to low-double digit growth, reflecting concerns over the company's current pipeline and market conditions.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares